· Mechanism
· Role
· Metabolism
· Toxicity
· ↑5HT activity -> ↑descending modulation (multiple receptor subtypes involved)
· Endocannabinoid reuptake inhibition -> central analgesia, tranquility (paracetamol’s active CNS metabolite AM404)
· Central COX inhibition: unclear effect and significance
· Other: nitric oxide, opioid pathways
· First step in the WHO analgesic ladder
· Minimal side effects, low risk of toxicity
· Reduces opioid use and opioid side effects
· Phase 2
o Glucuronidation ~55%
o Sulfation ~35%
· Phase 1
o CYP450 to NAPQI (N-acetyl P-benzquinonimine) ~10%
· With normal doses
o NAPQI + glutathione -> cysteine conjugate, mercaptopuric acid conjugate
· With high dose
o Conjugation pathways saturated
o ↑NAPQI production
o Glutathione exhausted (earlier if malnourished)
o ↑NAPQI accumulation
o Damage to hepatic proteins
o Centrilobular necrosis
o Acute liver failure
Feedback welcome at ketaminenightmares@gmail.com